Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Finished Goods: 2022-2024

Historic Finished Goods for Axsome Therapeutics (AXSM) over the last 3 years, with Dec 2024 value amounting to $9.0 million.

  • Axsome Therapeutics' Finished Goods rose 17.28% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year increase of 17.28%. This contributed to the annual value of $9.0 million for FY2024, which is 6.81% down from last year.
  • Per Axsome Therapeutics' latest filing, its Finished Goods stood at $9.0 million for FY2024, which was down 6.81% from $9.6 million recorded in FY2023.
  • In the past 5 years, Axsome Therapeutics' Finished Goods registered a high of $9.6 million during FY2023, and its lowest value of $1.6 million during FY2022.
  • Its 3-year average for Finished Goods is $6.7 million, with a median of $9.0 million in 2024.
  • Its Finished Goods has fluctuated over the past 5 years, first skyrocketed by 506.48% in 2023, then dropped by 6.81% in 2024.
  • Yearly analysis of 3 years shows Axsome Therapeutics' Finished Goods stood at $1.6 million in 2022, then surged by 506.48% to $9.6 million in 2023, then fell by 6.81% to $9.0 million in 2024.